Ocusphere Therapeutics Inc
OcuSphere Therapeutics is a biotechnology company focused on developing a scalable, non-viral gene therapy platform to treat hundreds of inherited retinal diseases (IRDs). Founded and led by patients, the company aims to provide affordable gene therapies for conditions that currently lack effective treatments and are prohibitively expensive. Their platform, 'Synthetic Virion', utilizes a modular design for customizable payload capacity, reduced immunogenicity, and scalable manufacturing. They are also developing an AI-driven promoter prediction tool using genomic AI to enhance precision in retinal genomics research. OcuSphere's pipeline includes treatments for USH2A, CRB1, RLBP1, CHM, and an LNP-DNA Eye Drop.
Ocusphere Therapeutics Inc
OcuSphere Therapeutics is a biotechnology company focused on developing a scalable, non-viral gene therapy platform to treat hundreds of inherited retinal diseases (IRDs). Founded and led by patients, the company aims to provide affordable gene therapies for conditions that currently lack effective treatments and are prohibitively expensive. Their platform, 'Synthetic Virion', utilizes a modular design for customizable payload capacity, reduced immunogenicity, and scalable manufacturing. They are also developing an AI-driven promoter prediction tool using genomic AI to enhance precision in retinal genomics research. OcuSphere's pipeline includes treatments for USH2A, CRB1, RLBP1, CHM, and an LNP-DNA Eye Drop.